[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2010059894A1 - Formations oculaires de norkétotifène - Google Patents

Formations oculaires de norkétotifène Download PDF

Info

Publication number
WO2010059894A1
WO2010059894A1 PCT/US2009/065252 US2009065252W WO2010059894A1 WO 2010059894 A1 WO2010059894 A1 WO 2010059894A1 US 2009065252 W US2009065252 W US 2009065252W WO 2010059894 A1 WO2010059894 A1 WO 2010059894A1
Authority
WO
WIPO (PCT)
Prior art keywords
norketotifen
percent
formulation
formulations
ocular
Prior art date
Application number
PCT/US2009/065252
Other languages
English (en)
Inventor
A.K. Gunnar Aberg
Keith Johnson
Original Assignee
Bridge Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bridge Pharma, Inc. filed Critical Bridge Pharma, Inc.
Publication of WO2010059894A1 publication Critical patent/WO2010059894A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Definitions

  • the present invention relates to compositions for administration of the compound RS-norketotifen, hereinafter called norketotifen.
  • This compound is useful for treating a variety of ocular disorders, including xerophthalmia and various forms of conjunctivitis and keratitis (US Patent 6,207,684).
  • norketotifen is 4-(4-piperidyliden)-9-oxo-9,10-dihydro-4H- benzo[4,5] cyclohepta[l,2-b]thiophene, which is a mixture of R-norketotifen and S- norketotifen.
  • excipients have now been tested for compatibility with norketotifen and certain excipients have now been found to be compatible with norketotifen.
  • compatible and incompatible excipients such as for example members of the classes Antioxidants, Buffers, Chelating agents, Emollients, Gelling agents, Humectants, Mucoadhesive agents, Preservatives, Solvents, Stabilizers, Surfactants, Tonicity modifying agents and Viscosity modifying agents, have been identified and are described herein. Numerous compositions using said excipients have been prepared and tested.
  • composition and “formulation” are used as synonyms herein.
  • the terms “about” and “approximately” are used as synonyms herein.
  • the terms “disorder” and “disease” are used as synonyms herein.
  • carrier and “solvent” are used as synonyms herein.
  • the terms “norketotifen” and “norketotifen HF” as used herein refer to the hydrogen fumarate salt of said compound.
  • the free base of norketotifen is herein called “norketotifen free base” or “norketotifen FB".
  • “about” means within the pharmaceutically acceptable limits found in the United States Pharmacopeia (USP-NF 21), 2003, or available at www.usp.org for amount of pharmaceutical ingredients.
  • Embodiments disclosed herein relate to compositions of norketotifen that are intended for the treatment of ocular disorders, such as xerophthalmic disorders, allergic disorders and inflammatory disorders as well as combinations thereof, and methods of treating ocular disorders by administration of such compositions.
  • xerophthalmia refers to conditions that are also called xerophthalmic disorders, keratoconjunctivitis sicca, keratitis sicca, sicca syndrome, dry eye syndrome, or dry eyes.
  • the present invention also relates to formulations of norketotifen that are intended for the treatment of allergic (atopic) ocular diseases, such as for example allergic conjunctivitis and various other types of ocular inflammatory diseases, such as for example keratitis, keratoconjunctivitis, non-allergic conjunctivitis and various forms of blepharitis (inflammation of the eyelids).
  • allergic ocular diseases such as for example allergic conjunctivitis and various other types of ocular inflammatory diseases, such as for example keratitis, keratoconjunctivitis, non-allergic conjunctivitis and various forms of blepharitis (inflammation of the eyelids).
  • Norketotifen is an active metabolite of ketotifen (Zaditor®, Novartis), which is used as an ocular medication for allergic disorders. Norketotifen has antihistaminic activity (Kennedy GR, 1982) that is about half of that of ketotifen when tested in vivo (Example 12.) Norketotifen is about ten times more active than ketotifen as anti-inflammatory compound (Example 13.)
  • NORKETOTIFEN Ketotifen is available commercially, for example from Sigma- Aldrich (Internet: Sigma-Aldrich.com/order).
  • Norketotifen can be made by demethylation of ketotifen according to the method described by Waldvogel et al. 1976, which publication is hereby incorporated by reference.
  • this use of norketotifen is limited by its inherent irritability, as well as the irritability of certain excipients that were previously thought necessary to formulate an effective medicament, taking into account various issues including the limited solubility of the active ingredient norketotifen.
  • racemic norketotifen is useful for the treatment of various ocular conditions, such as for example conjunctivitis and keratitis. Further descriptions concerning S-norketotifen and R-norketotifen were presented in US Patents 7,226,934 and 7,557,128, respectively. Said patents are hereby incorporated by reference. It has now been found that selected formulations of norketotifen are well tolerated by mammalian ocular tissues and have the surprising effect of decreasing or eliminating the ocular irritating activity of norketotifen when applied to the eye. Said selected formulations (herein called "preferred formulations") of norketotifen are suitable for daily topical administrations. Ocular administration of ophthalmic medication is the preferred route of administration.
  • norketotifen Due to its physicochemical properties and its pharmacological effects, such as low anti-muscarinic activity, norketotifen is well suited for ocular use.
  • ketotifen Ocular formulations of ketotifen have been described (US Patent 6,455,547) but are of no relevance for norketotifen since the physicochemical properties for norketotifen HF are vastly different from those of ketotifen — as an example, the water solubility for ketotifen is about 12.5 mg/ml and the water solubility of norketotifen is about 2.16 mg/ml.
  • compositions are depending on the physicochemical and the pharmacological properties of the active molecule(s) and the therapeutic effects sought.
  • norketotifen our research has now arrived at compositions that are acceptable to the patients, therapeutically efficacious, allowing for once- daily ocular administration or for repeated daily ocular administrations to mammals in need thereof, while decreasing or even inhibiting certain ocular side effects of norketotifen.
  • Selected ocular compositions have now been found, which offer pharmaceutical compatibility between the active ingredient and the excipients, optimize the therapeutic activities of norketotifen and decrease the ocular side effects thereof.
  • therapeutically effective (dose)” and “therapeutically efficacious (dose)” refer to a dose that yields therapeutic benefit to patients, which in the present case refers to therapeutic benefit to patients suffering from allergic and/or inflammatory condition(s).
  • the present invention may be useful for patients in need of medication for ocular inflammatory and ocular allergic disorders and for patients suffering from xerophthalmic disorders.
  • patients in this document refers to mammals, such as for example humans, dogs and cats. Preferred are human patients.
  • Patients suffering from ocular allergic and /or inflammatory disorders include individuals being diagnosed as suffering, for example, from various types of conjunctivitis, as for example allergic conjunctivitis, seasonal allergic conjunctivitis, chronic allergic conjunctivitis, atopic keratoconjunctivitis or vernal conjunctivitis.
  • conjunctivitis refers to all forms of the disease.
  • Keratitis is a condition in which the eye's cornea becomes inflamed.
  • keratitis refers to all forms of the disease.
  • dry eye disease 1' and " xerophthalmia” ' are used synonymously herein and refer to various disorders that are well known to those skilled in the art ot ophthalmology.
  • xerophthalmic disorders are keratoconjunctivitis sicca, age-related dry eye, Stevens-Johnson syndrome, Sjogren ' s syndrome, ocular cicatrical pemphigoid, blepharitis, corneal injury, infections, Riley-Day syndrome, congenital alacrima, nutritional disorders or deficiencies (including vitamin A deficiency), autoimmune and other immunodeficient disorder cmd side effects of medications such as for example anticholinergic drugs used for overactive bladder syndrome and urinary urge incontinence.
  • dry eye disease or ' 'xerophthalmia refer to all forms of the disease.
  • AU compositions intended for use in the eye are required Lo be sterile, endotoxin-free and foreign particulate free.
  • the term ' 'foreign particulate free indicates the absence of any particulate matter, but excl udes drug particles, controlled release micropartkulates and the like.
  • Conventional methods for the manufacture of sterile compositions include sterilization by moist heat (autodaving), sterilization by dry heat, ethylene oxide sterilization (gaseous sterilization ), exposure to ultraviolet rays or to gamma irradiation or sterilization by aseptic processing or filtration through sterilizing grade filters.
  • Norketotifen formulations for ocular administration that are described herein can be readily processed by standard manufacturing processes, which are well known to those skilled in the art.
  • the acidity of the final ocular composition should be between pH 4.0 to pH 6.5, preferably between pH 5.2 to pH 6.2.
  • the tonicity of final aqueous ocular solutions should be from 150 mOsm to 450 mOsm and preferably from 230 mOsm to 330 mOsm.
  • Therapeutically effective ophthalmic compositions of norketotifen, containing excipients that are compatible with this drug have now been developed and formulations, such as ocular solutions, ocular hydrophilic ointments and gels, ocular hydrophobic ointments, ocular emulsions and ocular liposome formulations, all containing norketotifen, have now been developed and are described herein. It was an objective to develop formulations of norketotifen that allow for once-daily ocular administration and for repeated ocular administrations from two to five times daily to patients in need thereof.
  • “Therapeutically effective" ocular solution formulations of norketotifen refer to concentration of norketotifen from 0.001 percent to 0.30 percent; more preferred are concentrations from 0.01 percent to 0.25 percent by weight.
  • “Therapeutically effective” formulations with one or more solubilizing excipient refer to norketotifen concentrations from 0.001 percent to 5.0 percent by weight, more preferred from 0.01 percent to 1.0 percent by weight.
  • An eyedropper device is usually used for the administration of ophthalmic solutions to the eye.
  • the volume of each drop depends on the construction of the device, the technique used to produce the drop and the viscosity of the solution being administered.
  • Commercial eyedroppers usually deliver drops with a volume of 50 ⁇ L.
  • one drop of norketotifen 0.1 percent equals an amount of 50 ⁇ g norketotifen.
  • a squeezable tube with a small tip is usually used for the administration of gels or ointments to the eye.
  • the amount administered depends on the technique used and the design of the tube.
  • the amount of the gel or ointment dosed is usually from about 20 mg to about 50 mg for each application.
  • norketotifen as used herein relates to the basic compound itself as well to any pharmaceutically acceptable salt thereof.
  • Preferred pharmaceutically acceptable salts of norketotifen are for example a hydrogen fumarate, a hydrochloride, a hydrobromide, a hydrogen maleate, or a hydrogen sulfate. More preferred salts of norketotifen are the hydrochloride salts and hydrogen fumarate salt. Most preferred is the hydrogen fumarate salt.
  • pharmaceutically acceptable salt and the like refer to salts prepared from pharmaceutically acceptable acids, such as for example fumaric, hydrobromic, hydrochloric, maleic and sulphuric acids.
  • terapéuticaally effective ocular formulations of norketotifen refers to solutions containing norketotifen in concentrations from about 0.001 percent to about 0.30 percent; more preferred are concentrations from 0.01 percent to 0.250 percent.
  • Formulations containing one or more excipient with solubilizing activity may contain higher concentrations of norketotifen than indicated above.
  • gels, ointments and solutions containing solubilizing excipients may contain norketotifen in concentrations in excess of 5.0 percent.
  • "therapeutically effective" ocular formulations containing one or more solubilizing excipient contain norketotifen in concentrations from about 0.001 percent to about 5.0 percent, more preferred are concentrations from about O.Olpercent to about 1.0 percent.
  • compositions which comprise norketotifen formulated together with carefully selected excipients.
  • the pharmaceutical compositions of the present inventions concern formulations of norketotifen that are intended for topical ophthalmic use by patients suffering from ocular disorders, such as allergic or inflammatory disorders or both allergic and inflammatory disorders.
  • composition and “formulation” are used as synonyms herein. If not stated to the contrary, all percent (%) concentrations in this document refer to percentage by weight (w/w).
  • the therapeutically useful pH-range of solutions of norketotifen was limited by decreased chemical stability of norketotifen at pH > 6.5 (Example 11).
  • the lowest tolerated pH of ocular formulations is known to be about pH 4, since formulations with pH ⁇ 4 may induce chemical burns (Dr Wright Productions, Handbook of Ocular Disease Management, 2009).
  • the acidity of ocular formulations of norketotifen should be from pH 4 to pH 6.5, preferably from about pH 5.2 to about pH 6.2.
  • the tonicity of norketotifen formulations should be isotonic to human tears (Benjamin et al., 1983; and Craig e al., 1995.) or slightly hypotonic. It was therefore determined that the tonicity should be from about 150 mOsm to about 450 mOsm, preferably from about 230 mOsm to about 330 mOsm.
  • mOsm is a measurement of osmolality and refers to milliosmoles per kilogram of solvent.
  • the viscosity of norketotifen formulations should be within a range that feels comfortable to the patient, while not causing blurring of the vision. Furthermore, the norketotifen formulations should have a viscosity that can be handled easily during manufacturing and filling. It was determined that the norketotifen formulations of the present invention should have viscosity of about 1.0 to about 100,000 centipoise (cP), preferably between about 2.0 to about 90,000 cP and most preferably from about 2.5 to about 75,000 cP, when tested at room temperature.
  • cP centipoise
  • centipoise water has the viscosity of 1 centipoise at 2O 0 C.
  • compatible refers to the compatibility between the excipient(s) and the active ingredient norketotifen.
  • AU compositions intended for use in the eye are required to be sterile.
  • the choice of an appropriate method for sterilization is within the scope of understanding of a person of ordinary skill in the art of manufacturing ocular dosage forms.
  • Norketotifen compositions, of the present invention which are stable to increased temperatures, can be sterilized by moist heat (autoclaving).
  • autoclaving relates to a standardized thermal heating procedure characterized by: Heating a test composition to 12O 0 C or more for a period of 15 minutes or more, wherein said composition is aqueous. Said aqueous composition is kept in a closed vessel, which vessel is typically a plastic or glass bottle.
  • the pressure during autoclaving is typically 1 bar or more.
  • the autoclaving may preferably range from 120 to 15O 0 C, more preferably from 120 to 14O 0 C; the time needed may preferably range from 15 to 120 minutes, more preferably from 15 to 60 minutes; and the pressure applied may preferably range from 1 to 20 bar, more preferably from lto 10 bar, and even more preferably form lto 5 bar.
  • ocular norketotifen compositions can be exposure to ultraviolet rays or to irradiation, such as gamma irradiation.
  • Formulations can also be processed asepl ⁇ cally, which includes filtration through sterilizing grade filters, which may have a nominal pore size of 0.22 ⁇ m.
  • Maintaining sterility in multiple-use containers is usually achieved by adding one or more preservatives to the formulations.
  • sterilized single-unit dose packages such as for example single unit dose vials, ampoules or syringes, containing a sterile norketotifen formulation, as described herein, may be used.
  • the manufacturing, handling and distribution of single-unit dose packages are expensive and the use thereof may be complicated to the patient.
  • formulations containing norketotifen are self-preserving (Example 9).
  • self-preserving as used herein means that said norketotifen formulations do not support microbial growth despite the absence of the addition ot any conventional preservatives in the formulation.
  • formulations do not support microbial growth means that the number of inoculated colonies in a formulation remain the same or decline in preservative challenge tests carried out on said formulation.
  • a self-preserving formulation of norketotifen will not need a preservative, such as for example BAK, to be included as an excipient in said formulation. Accordingly, when used in the claims, the term “consisting essentially of” means that any ingredient that if present in the formulation, would be present in an amount effective to have a preservative effect on the formulation, is excluded.
  • the self-preserving effects of the present norketotifen formulations may allow the use of very low concentrations of preservative agents .
  • a "very low concentration" of the preservative agent BAK is an amount corresponding to a concentration that is less than 0.001 percent by weight of said formulation.
  • a "very low concentration” of the preservative agent PHMB is an amount corresponding to a concentration that is equal or less than 1 pprn.
  • the preferred formulations of norketotifen prevent the expression of unwanted ocular effects of norketotifen or any excipient(s) being used,
  • the preferred norkefotifen formulations prevent or inhibit any unwanted effects on the cornea (such as for example the formation of opacifies), on the iris (such as for example congestion, swelling or reaction to light) or on the conjunctivae fsuch as tor example redness, swelling or discharge formation)
  • certain preferred formulations of norketotifen have the ability to completely prevent any and all ocular side effects of norketotifen even at the highest concentrations of norketo ⁇ fen that can be prepared in ocular solutions.
  • the preferred ocular formulations of norketotifen do not decrease the solubility of norketotifen, but actually increase said solubility,
  • the solubility of norketotifen at pli 4.0 was found Lo be 2.16 mg/m! in water and the solubility remained approximately the same as pH was increased (by adding MaOH) to pH 5,0, 6,0 or 7.0.
  • he solubility of norketotifen in buffered water was slightly decreased to 2.10 mg/ml at pH 8.6.
  • the solubility of norketotifen was sharply decreased at higher pH and ai pH 8.75 the solubility of norketofifen was decreased to approximately 1.0 mg/ml.
  • the solubility of norketotifen was about 2.4 mg/m! (pH 5.5).
  • the solubility on norketotifen could be significantly increased is certain formulations, such as geis and ointments where solvents were not water.
  • the solubility of norketotifen was about 10 mg/ml in propylene glycol.
  • Norketotifen compositions of the present invention can be filled into vials, ampoules, syringes or the like and then lyopb ⁇ ized. Lyophilized products, which are free from moisture, are then reconstituted before administration providing a prolonged shelf life.
  • Suitable excipients include specific antioxidants, buffers, chelating agents, emollients, emulsifiers, fillers, gelling agents, humectants, mucoadhesives, preservatives, solvents, stabilizers, surfactants, tonicity agents and viscosity modifying agents.
  • EDTA edetate
  • Another example is propylene glycol that is used in formulation S1009 (Table IB) as a solvent /moisturizer /tonicity modifier.
  • EDTA comprises the chemical compound ethylenediaminetetraacetic acid and the disodium and calcium disodium salts thereof.
  • EDTA and the salts thereof have many names, such as for example edetate, disodium edetade.
  • ED3A ethylenediaminetriacetic acid
  • ED3A ethylenediaminetriacetic acid
  • Antioxidants are compounds that act to slow or prevent the oxidation of other chemicals.
  • Suitable antioxidants that are compatible with norketotifen include sulfites, ascorbates, acetylcystein, butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT).
  • BHA butylated hydroxyanisole
  • BHT butylated hydroxytoluene
  • useful concentrations range from about 0.05 percent to about 3 percent, preferably 0.1 percent to 0.25 percent, by weight.
  • Buffering agents are used to adjust the pH of a solution.
  • the function of a buffering agent is to drive an acidic or alkaline solution to a certain pH range and prevent a change from this pH.
  • Buffering agents have variable properties — some are more soluble than others; some are acidic while others are basic.
  • Suitable buffering agents that are compatible with norketotifen include phosphates, boric acid, borates, citrates and acetates. Buffers will be used in the concentrations needed to stabilize the acidity between pH 4.6 and pH 6.5, preferably between pH 5.2 and pH 6.2.
  • the amount of each of the buffering compounds needed may range from about 0.01 percent to about 4 percent by weight, preferably from 0.05 percent to 1 percent by weight.
  • Ocular compositions with pH ⁇ 4.0 are usually not well accepted by patients and ocular compositions of norketotifen with pH > 6.5 have now been found to decrease long-term chemical stability.
  • the acidity of ocular norketotifen compositions should be between about pH 4 and about pH 6.5, preferably between pH 5.2 and pH 6.2.
  • compatible buffering agents can be used in all formulations mentioned herein. The acidity of all formulations described herein can be adjusted by changing the concentrations of the buffering agents or by adding an acid or a base as known to those skilled in the art.
  • Chelating agents which are often organic compounds, are also called chelants, or sequestering agents and have the ability to form a chelate complex with a substrate.
  • Known chelating agents are for example, edetate, proteins, polysaccharides, polynucleic acids and chelating polymers.
  • Suitable chelating agents compatible with norketotifen are edetate and chitosan polysaccharides. If needed, chelating agents may be used in concentrations from about 0.01 percent to about 10 percent, preferably from 0.01 percent to 2.0 percent by weight.
  • Some chelating agents, for example chitosan polysaccharides also have mucoadhesive properties. When needed, compatible chelating agents can be used in all formulations mentioned herein.
  • Emollients cause occlusion of mucous membranes by providing a layer of oil to slow water loss from mucous membranes of the eye. Emollients also act as humectants and thereby improve the water-holding capacity of the ocular tissues. Emollients also act as lubricants, whereby these agents add slip or glide to the mucous membranes of the cornea and the conjunctival membranes. Emollients can be used in the ocular formulations of the present invention only if said emollients meet the criteria of being active at ⁇ pH 6.0 and if they do not decrease the chemical stability of norketotifen.
  • Suitable emollients compatible with norketotifen include, for example, glycerin, propylene glycol, and hypromellose (hydroxypropyl methylcellulose, HPMC).
  • compatible emollients can be used in all formulations mentioned herein. If needed, said emollients can be used in concentrations from about 0.1 percent to about 10 percent and preferably in concentrations from 0.1 percent to 2 percent by weight in the norketotifen formulations described herein.
  • Gelling agents are used to thicken and stabilize liquid solutions, emulsions and suspensions, thereby inducing retention of the compositions in the ocular tear fluid. Gelling agents dissolve in solutions, giving an appearance of a more or less solid matter, while being mostly composed of a liquid.
  • suitable gelling agents compatible with norketotifen include edetate (EDTA), alginic acid and alginates, carrageenan, pectin, gelatin and gelling polymers.
  • EDTA edetate
  • alginic acid and alginates edetate
  • carrageenan alginic acid and alginates
  • pectin glatin
  • gelling polymers edetate
  • compatible gelling agents can be used in all formulations mentioned herein. Gelling agents can be used in concentrations from about 0.05 percent to about 10 percent and preferably in concentrations from 0.1 to 2.5 percent by weight.
  • In situ gelling agents may be included in ocular formulations of norketotifen and are instilled as drops into the eye and undergo sol-to-gel transition in the tear fluid, due, for example, to ion-triggered activation, pH- triggered activation or thermal activation.
  • Alginate is a gelling agent that can be used in combination with the viscosity-enhancing agent hydroxypropyl methylcellulose (HPMC). The rheological behavior of the alginate/HPMC solutions were retained in the presence of norketotifen and was found to be a useful ion-activated in situ gelling system for norketotifen-containing compositions.
  • Polyacrylic acid is a gelling agent in combination with the viscosity-enhancing agent hydroxypropyl methylcellulose (HPMC) and is a useful pH-triggered in situ gelling system for norketotifen-containing compositions.
  • Poloxamer 407 is a polymer with a solution viscosity that increases when its temperature is raised to the eye temperature (Hongyi et al. 2006). The temperature-sensitive rheological behavior of Poloxamer 407 or Poloxamer 407/188 mixtures was not influenced by the presence of norketotifen.
  • Suitable in situ gelling agents compatible with norketotifen were also found to include alginate /hydroxypropyl methylcellulose, poly aery lie acid/ hydroxypropyl methylcellulose.
  • In situ gelling agents as described above can be used in concentrations from about 0.5 percent to about 10 percent, preferably from 0.1 percent to 2.5 percent by weight. Poloxamers can be used in higher concentrations, up to 25 percent by weight.
  • Humectants can be used to soften biological tissues as they increase the water-holding capacity of ocular tissues, such as the cornea and the conjunctival membranes and certain humectants were found to be compatible with norketotifen and can be used in ocular formulations of norketotifen.
  • Suitable humectants that are found to be compatible with norketotifen include polyethylene glycol, sorbitol and propylene glycol. When needed, compatible humectants can be used in all formulations mentioned herein. Said humectants are used in concentrations from about 0.05 percent to about 10 percent, preferably from 0.1 percent to less than 4 percent and more preferably from 0.1 percent to 2 percent by weight.
  • Lubricants can hold moisture on the eye. Numerous polymers can be used as ocular lubricants. Suitable lubricants that are compatible with norketotifen include methylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, thiolated acrylic acid polymers, carbomer, carboxymethylcellulose sodium, chitosans, and polyisobutylcyanoacrylate. When needed, compatible lubricants can be used in all formulations mentioned herein. If needed, the concentrations of said lubricant is from 0.1 percent to 10 percent, preferably from about 0.1 percent to about 4 percent and more preferably from 0.1 percent to 2 percent by weight.
  • Mucoadhesive agents refer to materials that will adhere to mucus and mucosal membranes. Suitable mucoadhesives that are compatible with norketotifen formulations described here include thiolated acrylic acid polymers, chitosan, polyisobutylcyanoacrylate and ethylcellulose. Mucoadhesive polymers, such as mucoadhesive chitosan and mucoadhesive chitosan-coated microspheres or liposomes will be useful for prolonged delivery of norketotifen to the eye. Mucoadhesive agents can be used in concentrations from about 0.1 percent to about 10 percent, preferably from 0.1 to 2 percent by weight. If needed, compatible mucoadhesive agents can be used in all formulations mentioned herein.
  • norketotifen can be administered to patients as ocular mucoadhesive minitablets, microspheres and as ocular gel- forming minitablets (see Example 7 below).
  • Preservatives are substances that can be used to prevent the growth of microorganisms in ophthalmic formulations.
  • Suitable preservatives that are compatible with norketotifen include stabilized oxychloro complexes, benzalkonium chloride (BAK), polyhexamethylene biguanide (PHMB). Sorbic acid was found to be incompatible with norketotifen since this preservative decreased the stability of norketotifen solutions.
  • a suitable concentration of a stabilized oxychloro complex is from 0.003 percent to 0.01 percent by weight and a suitable concentration of BAK is from 0.0001 percent (1 ppm) to 0.05 percent (500 ppm) preferably 0.0001 percent to 0.02 percent by weight.
  • a suitable concentration of PHMB is from 0.00001 percent (0.1 ppm) to 0.005 percent (50 ppm), preferably from 0.0005 percent (5 ppm) to 0.00005 percent (0.5 ppm).
  • Any preservative mentioned here may be combined with one or more other preservatives for improved efficacy.
  • the concentrations of preservatives may be kept lower than shown here, including the case where no preservatives are used, since formulations containing norketotifen have now been found to be self -preserving.
  • ophthalmic compositions In addition to water, which is the preferred carrier, other solvents like polyethylene glycol (PEG) and /or propylene glycol (PG) can be used in ophthalmic compositions.
  • PEG polyethylene glycol
  • PG propylene glycol
  • Norketotifen HF was found to be soluble in a polyethylene glycol (PEG 300) up to 0.15 percent w/w.
  • Propylene glycol can be used as a solvent to obtain high concentrations of norketotifen in ophthalmic ointments and gels since norketotifen HF, has now, surprisingly, been found to be soluble in propylene glycol up to 1.0 percent by weight.
  • Norketotifen can be dissolved in water in concentrations up to 0.216 per cent by weight.
  • Suitable nonaqueous solvents include polyethylene glycol (about 0.1 percent to about 90 percent) and propylene glycol (about 0.1 percent to about 90 percent). Both BAK and PHMB were compatible with norketotifen and can be used in all formulations mentioned herein.
  • Stabilizers in ophthalmic formulations enhance the physical stability of ocular compositions, such as for example emulsions. It was found that several known stabilizers, such as for example xanthan gum and carbomers (acrylic acid polymers), were not compatible with norketotifen since hazy suspensions were formed. Suitable stabilizers that are compatible with norketotifen include methylcellulose, edetate, chitosan, hydroxypropylmethylcellulose and hydroxyethylcellulose.
  • stabilization when used herein relate to the stability of the pharmaceutical formulation in total and in particular to the stability of norketotifen when exposed to storage, oxygen, air, light and or heat (including high- temperature sterilization, such as autoclavation).
  • the compatible stabilizers listed here are usually used in concentrations from about 0.05 percent to about 4 per cent and preferably from 0.05 percent to 2 percent by weight.
  • Combined stabilizer/solubilizers may be used in formulations containing norketotifen. Such combined additional stabilizer/solubilizers are for example cyclodextrins.
  • a preferred cyclodextrin is in particular selected from the group of ( ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin, dimethyl- ⁇ -cyclodextrin and dimethyl- ⁇ - cyclodextrin.
  • concentrations are generally in the range of from about 0.01 percent to about 90 percent, more preferably in the range of from about 0.1 to about 20 percent by weight.
  • Surfactants reduce the surface tension of liquids, such as for example water.
  • Suitable surfactants that are compatible with norketotifen include nonionic surfactants, such as for example polysorbates, glyceryl stearate, lecithins, polyethoxylated castor oil derivatives and oxyethylated tertiary octylphenol formaldehyde polymers, which in combinations with norketotifen were all found to be less irritating to the eye than ionic surfactants, which may also be used.
  • compatible surfactants can be used in all formulations mentioned herein.
  • Surfactants are usually used in concentrations from about 0.05 percent to about 4 per cent and preferably from 0.1 percent to 2 percent by weight.
  • Tonicity-adjusting agents increase the effective osmolarity or effective osmolality of a formulation.
  • Hypertonic, hypotonic and isotonic solutions are defined in reference to a cell membrane by comparing the tonicity of the solution with the tonicity within the cell.
  • Ocular compositions preferably contain a tonicity- adjusting agent in an amount sufficient to cause the final composition to have an ophthalmically acceptable osmolality (generally 150 to 450 mOsm and preferably 230 to 330 mOsm).
  • Suitable tonicity-adjusting agents to be used with norketotifen may be of ionic and /or non-ionic type.
  • ionic type tonicity enhancers is sodium chloride and examples of non-ionic tonicity enhancing agents are, for example sorbitol and propylene glycol, which are compatible with norketotifen.
  • norketotifen formulations may include for example sodium chloride in concentrations from about 0.1 to about 0.9 per cent by weight, sorbitol in concentrations from about 0.1 to about 10 per cent or propylene glycol in concentrations from about 0.1 to about 10 percent by weight. If needed, compatible tonicity-adjusting agents can be used in all formulations mentioned herein. All ophthalmic formulations of norketotifen were adjusted to be approximately iso- osmotic to human tears (Benjamin et al., 1983; Craig et al., 1995.)
  • Viscosity-adjusting agents increase the internal friction ("thickness") of a formulation.
  • the ophthalmic solutions of the present invention may contain one or more viscosity-adjusting agent and have a viscosity of 1.0 to 100,000 cP, preferably between 2.0 to 90,000 cP, and most preferred between 2.5 and 75,000 cP, which is acceptable since compositions in this range of viscosity feel comfortable to the eye and do not cause blurring of the vision.
  • Viscosity modifying agents can be used in ophthalmic compositions and are substances that have the ability to cause thickening (increase the viscosity) of ophthalmic formulations. Viscosified solutions are accepted to a great degree by patients, mainly because of the ease of administration.
  • Viscosity modifying agents such as for example xanthan gum, were not compatible with norketotifen.
  • Viscosity modifying agents that are compatible with norketotifen include edetate, methylcellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, polyethylene glycol, propylene glycol alginate, chitosan, and tragacanth.
  • the term "hydrogels" is often used for viscosity enhancing excipients, particularly in artificial tears and refers to a colloid with high gelling ability. If needed, compatible viscosity-adjusting agents can be used in all formulations mentioned herein.
  • the concentrations of the selected viscosity modifying agents range from about 0.1 per cent to about 10 per cent by weight, and preferably between 1 per cent and 5 per cent.
  • Sorbitol may be used as a combined tonicity- adjusting and viscosity-adjusting excipient in a concentration range from about 0.1 to about 10 per cent, preferably from 2 per cent to 5 per cent.
  • excipients can be used that have bioadhesive properties, such as for example mucoadhesive excipients, or the formulation can be made more viscous. Both strategies are included in the present invention.
  • compositions containing norketotifen are packed in opaque plastic containers that may be sterilized using for example ethylene oxide or gamma radiation.
  • a preferred container for an ophthalmic product may be equipped with an eyedropper.
  • Single-dose containers may be used and have advantages that are obvious to those skilled in the art. COMPOSITIONS COMPATIBLE WITH NORKETOTIFEN
  • compositions such as topical ophthalmic solutions, topical ophthalmic gels, topical hydrophilic ophthalmic ointments, topical ophthalmic emulsions, and topical ophthalmic liposome compositions were prepared as demonstrated in the following Examples. The prepared formulations were tested for physical appearance and stability (refrigerated, room temperature, and at increased temperatures) using analytical methodology as described in Example 10.
  • Example 10 An HPLC method for the determination of concentrations of norketotifen was developed (Example 10).
  • the excipients used in the present compositions can be analyzed using standard methods that are well known to those skilled in the art.
  • Preferred solution formulations containing norketotifen may contain excipients at different concentrations from those shown in Tables IA and IB.
  • Norketotifen HF 0.0345 percent is equivalent to norketotifen FB 0.025 percent.
  • Norketotifen may be used in concentrations from 0.01 to 0.3 percent.
  • BAK-concentration is from 0.0001% to 0.001%, preferably 0.0005%
  • pH is between 4.6 and 6.2, preferably 5.5.
  • Norketotifen HF 0.0345 percent is equivalent to 0.025 percent norketotifen FB.
  • Norketotifen HF 0.208 percent is equivalent to 0.15 percent norketotifen FB.
  • Norketotifen HF may be used in concentrations from 0.01 % to 0.3 %.
  • pH is between 4.6 and 6.2, preferably adjusted to 5.5 .
  • the tonicity can be adjusted by adding a tonicity-adjusting agent to obtain the preferred tonicity.
  • the viscosity can be adjusted by a viscosity-modifying agent to obtain the preferred viscosity.
  • the final acidity can be adjusted by adjusting the concentrations of the buffering agents or by adding an acid or a base.
  • the solution formulations were prepared by adding the excipients, one at a time to an appropriate amount of water, followed by mixing until dissolved. Once all excipients had been added and dissolved, norketotifen was added to the solution of excipients and mixed continuously until dissolved.
  • the acidity of the solutions was measured and adjusted by modifying the buffer system or by adding an acid or a base solution to the desired pH. If needed, viscosity and tonicity were adjusted as indicated above.
  • Preferred ophthalmic hydrophilic ointments or gels containing norketotifen may contain excipients at concentrations that are different from those shown in Table 2.
  • Ophthalmic hydrophilic ointments or gels containing norketotifen may contain excipients that are different from those shown in Table 2.
  • Topical hydrophilic ophthalmic gel and ointment compositions containing norketotifen can keep the drug in the eye for an extended period of time and the prolonged exposure will enhance drug delivery.
  • Ophthalmic hydrophilic ointments and gels were made, comprising norketotifen at concentrations that were usually between 0.010 percent and 1.0 percent (w/w, calculated as free base), although such formulations may contain in excess of 5.0 percent of norketotifen.
  • Said hydrophilic ointment and gel formulations have a viscosity that ranged from 5.000 to 500,000 cP, preferably from 20,000 to 200,000 cP.
  • thickeners /gelling agents are polyethylene glycol 300 and/or polyethylene glycol 3350 and/or polyethylene sorbate (polysorbate) and/or chitosan.
  • a compatible surfactant such as poloxamer 407 can also be added, preferably in a concentration less than 25 percent, more preferred in a concentration less than 20 percent by weight.
  • ophthalmic hydrophilic ointments and gels, containing norketotifen could also contain selected excipients, such as humectants such as for example sorbitol, viscosity modifying agents such as for example methyl cellulose, tonicity agents such as for example NaCl or propylene glycol, chelating agents such as for example edetate or polysaccharides, buffers such as for example phosphate buffers, surfactants such as for example glyceryl stearate, mucoadhesives such as for example polyisobutylcyanoacrylate, antioxidants such as for example BHA or BHT and preservatives such as for example BAK or PHMB. Suggested concentrations of these excipients are as shown previously in this document.
  • gels and ophthalmic hydrophilic ointments were designed for once- daily ocular administration or for repeated administrations from two to five times daily.
  • the selected hydrophilic ointment/gel in Table 2 is thick but miscible with water. This composition can hold the drug product in the eye of the patient for an extended time, which will enhance drug delivery.
  • Table 2 An example of a preferred topical hydrophilic ophthalmic ointment or gel containing norketotifen.
  • Batch OG1009 used a mixture of the polyethylene glycols PEG 300 and PEG 3350 as solvent for norketotifen.
  • the composition of Table 2 was prepared by adding the two polyethylene glycols to a suitable container and heating to 60-65 0 C. This heating step melts the high molecular weight polyethyleneglycol. Next, norketotifen was added and the composition was mixed until the active ingredient was dissolved. Finally, the composition was cooled with mixing to allow the ointment /gel to thicken. The viscosity was 30,000 cP or greater. The pH range for these compositions was not measured since the formulations were non-aqueous. If needed, the tonicity can be adjusted by adding a tonicity-adjusting agent to obtain the preferred tonicity. If needed, a preservative can be added.
  • the concentration of norketotifen HF can be from about 0.001% to about 0.15% by weight if dissolved in PEG 300 and from about 0.001% to about 0.25% in a mixture of PEG 300 and PEG 3350.
  • compositions for topical hydrophobic ophthalmic ointments containing norketotifen hydrogen fumarate (HF) is shown in Table 3.
  • Preferred hydrophobic ophthalmic ointments containing norketotifen may contain excipients at concentrations that are different from those shown in Table 3.
  • Hydrophobic ophthalmic ointments containing norketotifen may contain excipients that are different from those shown in Table 3.
  • the tested hydrophobic ointments were not miscible with water. These compositions can hold the drug product in the eye of the patient for an extended time and will enhance drug delivery.
  • Ophthalmic hydrophobic ointments and gels may contain norketotifen at concentrations between 0.001 percent and 5.0 percent, more preferably between 0.01 percent and 1.0 percent.
  • Said ophthalmic hydrophobic ointments and gel solutions were having viscosity in the range of range from 5,000 to 500,000 cP and preferably from 20,000 to 200,000 cP.
  • Said ophthalmic hydrophobic ointments and gels have tonicity between 150 and 450 mOsm, preferably between 230 and 330 mOsm.
  • Said ophthalmic hydrophobic ointments and gels can also contain other excipients, such as humectants, viscosity modifying agents, tonicity agents, chelating agents, buffers, surfactants, mucoadhesives, antioxidants and preservatives.
  • Said ophthalmic hydrophobic ointments and gels were designed for once-daily ocular administration or for repeated ocular administrations from two to five times daily to a mammal in need thereof. Table 3.
  • Batch HO1012 contained propylene glycol as a solvent for norketotifen, glycerol stearate and cetyl alcohol as surfactants and white petrolatum as base.
  • the hydrophobic ointment was prepared by dissolving norketotifen in propylene glycol. Next, glyceryl stearate, cetyl alcohol, and white petrolatum were added to a suitable container and heated to 65-70 0 C. This heating step melts the surfactants and the petrolatum. Next, norketotifen solution was slowly added and the composition mixed until the solvent was dispersed. Finally, the composition was cooled with mixing to allow the ointment to thicken.
  • acidity can be adjusted by adding an acid solution or a base solution to obtain the preferred acidity.
  • tonicity can be adjusted by adding a tonicity-adjusting agent to obtain the preferred tonicity.
  • viscosity can be adjusted by a viscosity-modifying agent to obtain the preferred viscosity. If needed, a preservative can be added.
  • EXAMPLE 4 Ophthalmic Emulsions Two examples of preferred compositions for topical ophthalmic emulsions containing norketotifen hydrogen fumarate (HF) are shown in Table 4 below (E1012 and E1015). Batches E1112 and E1115 were identical to E1012 and E1015, but were without the preservatives.
  • Topical ophthalmic emulsions containing norketotifen may contain excipients that are different from those shown in the examples in Table 4.
  • Ophthalmic emulsions were made, comprising norketotifen at concentrations between 0.01 percent and 5.0 percent, preferably between 0.01 percent and 1.0 percent.
  • Said ophthalmic emulsions were having a viscosity in the range from 1.0 to 300,000 cP and preferably from 2.0 to 90,000 cP and most preferred from 2.5 to 75,000 cP.
  • Said ophthalmic emulsions had osmolality between 150 and 450 mOsm and most preferably between 230 and 330 mOsm.
  • Said ophthalmic emulsions had pH of 4 to 7, preferably pH 5.2 to 6.2.
  • Said ophthalmic emulsions could also contain excipients, such as humectants, viscosity modifying agents, tonicity agents, chelating agents, buffers, surfactants, mucoadhesives, antioxidants and preservatives.
  • excipients such as humectants, viscosity modifying agents, tonicity agents, chelating agents, buffers, surfactants, mucoadhesives, antioxidants and preservatives.
  • the batches E1012 and E1015 contained a phosphate buffer, propylene glycol as solvent /moisturizer /tonicity modifier, parabens as preservatives, castor oil and polyoxyl castor oil as surfactants and methylcellulose (if used) as a stabilizer /viscosity modifier.
  • Batches E1112 and E1115 were identical to E1012 and E1015, but were without the preservatives.
  • acidity was adjusted over a wide range. It was determined that emulsions can be used at pH of about 5.0 to about 7.0; the preferred acidity is pH 5.5 to pH 6.0.
  • the selected emulsions in Table 4 were prepared by adding propylene glycol, parabens (if used), castor oil, ethoxylated castor oil, and water to a suitable container. The contents of the container were sonicated with a 1/2" ultrasonic probe (Sonics Inc. Vibra Cell) for 20 minutes. The resulting emulsion droplets were mostly less than 0.5 microns. The emulsion was filtered through a 0.22- micron cellulose acetate filter. After filtration, norketotifen, buffer salt, and polymer (if used) were added. If needed, the tonicity can be adjusted by adding a tonicity-adjusting agent to obtain the preferred tonicity. The viscosity of norketotifen emulsions can be adjusted by a compatible viscosity-modifying agent in an amount that is needed to obtain the preferred viscosity.
  • EXAMPLE 5 Ophthalmic Liposome Compositions An example of a preferred ophthalmic liposome composition containing norketotifen hydrogen fumarate (HF) is shown in table 5. Preferred ophthalmic liposome compositions containing norketotifen may contain excipients of concentrations that are different from those shown in Table 5. Ophthalmic liposome compositions containing norketotifen may contain excipients that are different from those shown in Table 5.
  • Ophthalmic liposome compositions were made, comprising norketotifen at concentrations preferably between 0.01 percent and 0.50 percent. Said ophthalmic liposome compositions were having a preferred viscosity that ranged from 1.0 to 100,000 cP and more preferably from 2.0 to 90,000 cP. Said ophthalmic liposome compositions were having an osmolality between 150 and 450 mOsm, preferably between 230 and 330 mOsm. Ophthalmic liposome compositions have pH of 4 to 7, preferably pH 5.2 to 6.2. The liposome compositions are approximately iso- osmotic.
  • Said ophthalmic emulsions also contained excipients, such as humectants, viscosity modifying agents, tonicity agents, chelating agents, buffers, surfactants, muco-adhesives, antioxidants and preservatives.
  • excipients such as humectants, viscosity modifying agents, tonicity agents, chelating agents, buffers, surfactants, muco-adhesives, antioxidants and preservatives.
  • Said ophthalmic emulsions were designed for once-daily ocular administration or for repeated ocular administrations from two to five times daily to a mammal in need thereof.
  • Incorporating norketotifen in a selected liposome composition will enhance residence time in the eye and improve ocular drug delivery to the tissues.
  • a preferred liposome composition containing norketotifen is shown in Table 5 below. The acidity can be changed by adjustment of the buffer or by adding an acid or a base as know as known to those skilled in the art. Table 5. Example of a preferred ophthalmic liposome composition containing norketotifen HF.
  • quantum sufficit pH is 4.6 to 6.2, preferably about 5.5.
  • Batch LIPlOIl contained dibasic sodium phosphate as a phosphate buffer, glycerin as a moisturizer /tonicity modifier, benzalkonium chloride as a preservative and soy lecithin and cholesterol as surfactants.
  • emulsions can be used at an acidity from about pH 5.0 to about pH 7.0; the preferred acidity is pH 4.6 to pH 6.2; most preferred is pH 5.5.
  • liposome compositions containing norketotifen lecithin and cholesterol were dissolved in ethanol and added to a suitable container. Ethanol was evaporated leaving behind a lipid film. The remaining components of the composition were dissolved in water and this solution was added to the lipids to form a coarse dispersion of vesicles. This dispersion was sonicated with a 1/2" ultrasonic probe (Sonics Inc. Vibra Cell) for 15 minutes. The resulting liposomes were mostly less than 0.5 microns. The liposome composition was filtered through a 0.22-micron cellulose acetate filter.
  • the tonicity can be adjusted by adding a tonicity-adjusting agent to obtain the preferred tonicity. If needed, the viscosity can be adjusted by a viscosity-modifying agent to obtain the preferred viscosity.
  • Ophthalmic compositions containing norketotifen free base may contain excipients that are different from those shown in Tables IA, IB or 7.
  • compositions containing solutions of norketotifen FB represent a challenge due to the low water solubility of the free base. It has now been found that norketotifen FB can be dissolved in propylene glycol, glycerin, ethanol and isopropyl alcohol.
  • Surfactants such as for example polysorbate 80, polysorbate 20, poloxamer 407, poloxamer 188, polyoxyl 40 stearate or sorbitan monolaurate can also be used to dissolve norketotifen FB.
  • Liposomes as for example those made with phospholipids can also be used with the free base of norketotifen.
  • Norketotifen FB can also be formulated as a suspension and other formulations of the present invention.
  • emulsions can be used at pH of about 5.0 to about 7.0; the preferred acidity is pH 5.5.
  • An example of a preferred suspension containing norketotifen free base is shown in Table 6, below, where all percent are w / w.
  • the tonicity can be adjusted by adding a tonicity-adjusting agent to obtain the preferred tonicity.
  • the viscosity can be adjusted by a viscosity-modifying agent to obtain the preferred viscosity.
  • a preservative such as for example BAK may be added in concentrations shown previously in this document.
  • Norketotifen ocular minitablets using pregelatinized starch, hydroxypropylcellulose and Avicel and containing 5 percent Carbopol as the bioadhesive polymer (to reduce the risk for expulsion) and one or more water- insoluble polymers, such as ethylcellulose, unmodified or thiolated polyacrylic acid are prepared by compression. Minitablets are placed under the eyelid of rabbits. The effects on tear-film stability are examined using fluorescein staining after single dosing. Preliminary results indicate that inserts containing thiolated polyacrylic acid offer prolonged fluorescein concentration on the eye.
  • Gel-forming ocular minitablets may also be used as an ocular dosage form for norketotifen.
  • Test formulation in volumes of 0.1 ml were instilled into the conjunctival sac of six rabbit eyes of groups. Said volume of each formulation was repeatedly instilled every 30 minutes for 3 hours (a total of seven instillation into the eyes of rabbits. Ocular irritation was scored according to both Draize et al., 1944 and Kay and Calandra, 1962. Scorings were performed before each instillation and 30 minutes, 3 hours and 24 hours after the last instillation.
  • BAK benzalkonium chloride
  • Preservative challenge tests slightly modified after U.S. Pharmacopeia 51 Antimicrobial Effectiveness Testing, were performed.
  • USP (51) is a standard test used to determine the effectiveness of antimicrobial substances in ophthalmic products. The present tests were using 150 ml of each formulation and covered five organisms: Escherichia coli (fermentative G -), Pseudomonas aeruginosa (non- fermentative G -), Staphylococcus aureus (G +), Aspergillus niger (fungus) and Candida albicans (yeast).
  • the number of inoculated cells was 0.5xl0 5 per mL and the incubation temperature was 25 0 C (rt) for all inoculations.
  • Plating for measuring of recoveries were performed weekly over 4 weeks. If the numbers of cell colonies remained constant or were declining for all five microorganisms, the norketotifen formulation was defined as having self -preserving qualities; if the numbers of colonies increased for any of the five microorganisms, the formulations were not considered as having self-preserving activity.
  • Tests were performed at pH 4.0, 4.5, pH 5.0 and pH 6.0 and with formulations containing 0.208 percent norketotifen HF. All formulations referred to here were devoid of preservatives and contained: EDTA 0.1 %; Boric acid 0.095 %; Sorbitol 4.6 % and water q.s. (see Table IA: NOBAK formulations).
  • Ocular formulations of norketotifen according to the present invention can be used without preservatives in formulation with pH > 5.0.
  • the norketotifen hydrogen fumarate salt and other acceptable salt forms are acid salts of a weak base.
  • the salts can be expected to have fairly constant solubility over a wide pH range.
  • Formulations that contain an excipient or a combination of excipients that decrease the solubility of the active ingredient may not be useful.
  • ACN acetonitrile
  • TFA trifluoroacetic acid
  • the HPLC system was a HP 1050 with a variable wavelength detector. Over a range of 0.025 to 0.1 mg/mL, the assay showed good linearity with a correlation coefficient greater than 0.999. The relative standard deviation was approximately 0.3 percent for the main peak area.
  • HPLC assay described here was also used for determination of concentrations of norketotifen in the compositions of the present invention. Prior to analysis, norketotifen was extracted from the ophthalmic compositions, using standard methods, well known to those skilled in analytical chemistry.
  • the solubility of norketotifen at pH 4.0 was found to be 2.16 mg/ml in (unbuffered) water and the solubility remained approximately the same as pH was increased (by adding NaOH) to pH 5,0, pH 6.0 and pH 7.0.
  • the water solubility of norketotifen was decreased to 2.10 mg/ml at pH 8,6.
  • the water solubility of norketotifen was sharply decreased at higher pH and at pH 8.75 the solubility of norketotifen was decreased to approximately 1.0 mg/mL
  • the solubility of norketotifen was from about 2.4 mg/mi to about 2,7 rng/ml (pH 5.S), representing an improved solubility when compared with solubility in water.
  • the solubility oi norketotlien was significantly increased in certain tormulations, such as gels and ointments where solvents were not water. Fh us, the solubility of norket ⁇ tifen was about 10 rng/m! in formulation OGl ⁇ O Q f 1 able 2), where the solvent was a mixture of two polyethylene glycols.
  • Table 9A Stability of a formulation containing benzalkonium chloride.
  • Formulation See Table IA: LOBAK; pH 5.5. Concentrations are in mg/ml.
  • Table 9B Stability of a norketotifen formulation without benzalkonium chloride.
  • Formulation See Table IA: NOBAK; pH 5.5. Concentrations are in mg/ml.
  • Table 9C Stability of a norketotifen formulation without benzalkonium chloride.
  • Formulation See Table IA: NOBAK; pH 6.5. Concentrations are in mg/ml.
  • NOBAK at pH 5.5 are stable over a prolonged period as substantiated by the results from the accelerated stability tests at 4O 0 C and 55 0 C.
  • Table 9C demonstrates that norketotifen is not stable in solution formulations of pH 6.5 under conditions of accelerated testing (55 0 C).
  • mice Male rats (150-200 g) were starved overnight and twelve hours after dorsal depilation, the animals were dosed orally with the test compound(s). Four dorsal test areas were marked with permanent ink. Exactly 60 min after the dosing of the test compound, two intradermal injections of histamine (50 microliter; 1.0 mg/ml of histamine di-HCl) were performed, one on each side on the back of the animal. Two intradermal injections of the vehicle for the histamine solution were also performed. Evans blue dye (20 mg/kg) was injected iv 1 minute prior to the intradermal injections of histamine and the histamine vehicle.
  • Ketotifen 10 24 ⁇ 2 22 ⁇ 3 2 97
  • Norketotifen 50 10 ⁇ 1 12 ⁇ 1 0 100
  • ketotifen and norketotifen are potent antihistaminic compounds.
  • the dose/ response curves for ketotifen and norketotifen were not parallel.
  • Ketotifen was approximately twice as potent as norketotifen as an antihistamine at dose levels offering 75% inhibition of the histamine effect (IC 75).
  • Both ketotifen and norketotifen were more potent than the reference compound (diphenhydramine).
  • ketotifen was more potent than norketotifen and both compounds were more potent than diphenhydramine (Benadryl®). It is also concluded that norketotifen was well absorbed in rats after oral administration.
  • Anti-inflammatory activity was measured as effects on granulocyte activation ("mast cell stabilization").
  • the calcium ionophore A23187 was used to increase intracellular calcium concentration of the granulocytes.
  • Those skilled in the art of pharmacology realize that the presently used A23187-method mimics in vivo activation, initiated by IgE- and cAMP-induced increase of the intracellular calcium concentration, which in turn triggers a release of inflammatory mediators (such as histamine) from intracellular granulae, which is a process that is usually referred to as granulocyte "activation.”
  • the concentrations of norketotifen and ketotifen used here had to be relatively high, since the validated method for in vitro granulocyte activation uses high concentrations, high temperatures and a relatively long exposure time for the calcium ionophore.
  • Table 11 Inhibition of histamine release (IC50).
  • norketotifen was about ten times more potent than ketotifen as an inhibitor of human granulocyte activation, which is an anti-inflammatory effect.
  • Ophthalmic compositions of norketotifen may contain one or more additional, therapeutically active ingredients.
  • such combination compositions may contain one or more anti-inflammatory drug, such as for example a steroid belonging to the class consisting of corticosteroids, such as for example rimexolone (Vexol®, Alcon), fluorometholone (generic), prednisolone acetate (generic), loteprednol etabonate (generic), dexamethasone (generic) and difluprednate (DurezolTM, Sirion), or an NSAID, such as for example nepafenac (NevanacTM, Alcon), diclofenac (VoltarenTM, Novartis), ketorolac (AcularTM, Allergan), bromfenac (XibromTM, Ista), ibuprofen (generic) and indomethacin (generic).
  • corticosteroids such as for
  • such combination compositions may contain one or more immunosuppressants, such as cyclosporine (generic), tacrolimus (ProtopicTM, Fujisawa) and pimecrolimus (Elidel®, Novartis).
  • immunosuppressants such as cyclosporine (generic), tacrolimus (ProtopicTM, Fujisawa) and pimecrolimus (Elidel®, Novartis).
  • such combination compositions may contain one or more antimicrobial agents, such as for example aminoglycosides (e.g. neomycin), quinolones (e.g. ofloxacin), macrolides (e.g. azithromycin), polypeptides (e.g. bacitracin), sulfonamides (e.g. sulfacetamide), or combination products (e.g. polymyxin B).
  • antimicrobial agents such as for example aminoglycosides (e.g. neomycin), quinolones (e.g. ofloxacin), macrolides (e.g. azithromycin), polypeptides (e.g. bacitracin), sulfonamides (e.g. sulfacetamide), or combination products (e.g. polymyxin B).
  • Norketotifen can also be dissolved and administered in an oil-base composition or norketotifen can be dissolved in the oil phase of an oil-in-water emulsion system, which confers certain advantages to the patient, such as higher drug concentrations, minimal decomposition of norketotifen by hydrolysis, and lubrication and improved comfort to the eye.
  • Norketotifen can also be administered via the nasal route, the oral route or various parenteral routes using compositions described herein and devices known to those skilled in the art.
  • Regular or controlled release tablets or capsules contain from 1 mg to 20 mg norketotifen.
  • Combinations of routes, such as for example oral doses combined with topical ocular doses may have advantages, as known to those skilled in the art of drug formulations.
  • Micronized norketotifen can be used in ocular compositions of norketotifen and have particle sizes where >90 percent of the material is ⁇ 10 microns. Also nanoparticles of norketotifen can be used in ocular compositions thereof and have particle sizes where >90 percent of the material is ⁇ 1 micron.
  • Norketotifen has now been found to be a potent wound healing modulator and can be used to facilitate ocular surface re-epithelization and to prevent corneal haze resulting from scar formation due to inflammation. Similar effects have previously been described for ketotifen and cyproheptadine (USP 5624893) and olopatadine (USP 11/947041).
  • the formulations of norketotifen described herein are suitable vehicles for the delivery of norketotifen to the eyes of patients in need of a wound healing modulator.
  • Norketotifen HF solutions may contain concentrations containing about 0.02% to 0.21% norketotifen. Solutions containing solubilizers may have higher concentrations of norketotifen.
  • emulsions, gels, ointment, suspensions and similar formulation may contain concentrations of up to 4 %. All equivalents are included in the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur des compositions ophtalmiques contenant du norkétotifène et sur des procédés de fabrication de celles-ci, et sur l'utilisation de celles-ci. Les procédés comprennent également l'administration aux yeux d'un mammifère qui en a besoin de compositions ophtalmiques topiques contenant du norkétotifène.
PCT/US2009/065252 2008-11-21 2009-11-20 Formations oculaires de norkétotifène WO2010059894A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19988308P 2008-11-21 2008-11-21
US61/199,883 2008-11-21

Publications (1)

Publication Number Publication Date
WO2010059894A1 true WO2010059894A1 (fr) 2010-05-27

Family

ID=42196895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/065252 WO2010059894A1 (fr) 2008-11-21 2009-11-20 Formations oculaires de norkétotifène

Country Status (2)

Country Link
US (2) US8765787B2 (fr)
WO (1) WO2010059894A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066052A1 (fr) * 2015-10-15 2017-04-20 Bridge Pharma, Inc. Formulations et méthodes de traitement de pression intraoculaire élevée

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2164960A2 (fr) 2007-05-25 2010-03-24 North Carolina State University Plate-forme pour l'apport, ciblé sur des cellules, de nanoparticules virales
WO2010047681A1 (fr) * 2008-10-24 2010-04-29 Bridge Pharma, Inc. Traitement de xérophthalmie à l'aide de norkétotifène
WO2010059894A1 (fr) 2008-11-21 2010-05-27 Bridge Pharma, Inc. Formations oculaires de norkétotifène
US10227289B2 (en) 2010-05-07 2019-03-12 Medicus Biosciences, Llc Methods for treating diseases of the lung
US11083821B2 (en) 2011-08-10 2021-08-10 C.P. Medical Corporation Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules
US10111985B2 (en) 2011-08-10 2018-10-30 Medicus Biosciences, Llc Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules
KR101330652B1 (ko) * 2012-02-28 2013-11-18 (주)시지바이오 성장인자 담지 가능한 유착방지용 고분자 조성물
CA2873105C (fr) 2012-05-11 2018-01-16 Medicus Biosciences, Llc Traitements a base d'hydrogel biocompatible pour traiter un decollement de la retine
US8778971B2 (en) 2012-10-23 2014-07-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in companion animals
US8557846B1 (en) 2012-10-23 2013-10-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in dogs
US20140120121A1 (en) * 2012-10-30 2014-05-01 Bridge Pharma, Inc. Medicinal treatment of atopic inflammatory diseases
US20150272941A1 (en) 2012-10-30 2015-10-01 Bridge Pharma, Inc. Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen
WO2014120293A1 (fr) * 2013-01-31 2014-08-07 Sentiss Pharma Pvt.Ltd. Formulations ophthalmiques
US20140377210A1 (en) * 2013-06-21 2014-12-25 Gnt, Llc Artificial tear compositions
US9439895B2 (en) 2013-08-06 2016-09-13 Bridge Pharma, Inc. Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients
US9345697B2 (en) 2013-08-06 2016-05-24 Bridge Pharma, Inc. Methods of treatment of non-histaminic pruritus
US9138431B2 (en) 2013-08-06 2015-09-22 Bridge Pharma, Inc. Methods of treatment of histamine H-4 receptor-related pruritus
US20150335704A1 (en) * 2014-05-23 2015-11-26 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
AU2017325010A1 (en) 2016-09-08 2019-03-28 Emergo Therapeutics, Inc. Mast cell stabilizers for treatment of hypercytokinemia and viral infection
JP2019533018A (ja) 2016-10-18 2019-11-14 エマーゴ セラピューティクス，インク． 慢性炎症状態の処置の為の肥満細胞安定剤
KR102189740B1 (ko) * 2020-07-24 2020-12-14 (주)시지바이오 유착방지용 고분자 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207684B1 (en) * 1997-06-09 2001-03-27 Bridge Pharma, Inc. Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use
US20020037883A1 (en) * 2000-07-26 2002-03-28 Alcon Universal Ltd. Process for manufacturing compositions containinig ciprofloxacin and hydrocortisone

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3704907A1 (de) * 1987-02-17 1988-08-25 Bayer Ag Topisch anwendbare zubereitungen von gyrase-inhibitoren in kombination mit kortikosteroiden
US5369095A (en) * 1990-02-14 1994-11-29 Alcon Laboratories, Inc. Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
US5624893A (en) * 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
IL114193A (en) * 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
US5939426A (en) * 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
EP0938896A1 (fr) * 1998-01-15 1999-09-01 Novartis AG Compositions pharmaceutiques autoclavables contenant des agents de chelation
CZ301851B6 (cs) * 1998-04-02 2010-07-07 Novartis Ag Zpusob stabilizace farmaceutických prostredku speciálním použitím antioxidantu
CA2383222C (fr) * 1999-09-13 2008-11-18 Bridge Pharma, Inc. Isomeres de ketotifene optiquement actifs et metabolites therapeutiquement actifs
ATE400258T1 (de) * 2002-12-13 2008-07-15 Euro Celtique Sa Transdermales buprenorphin-dosierschema zwecks schmerzstillung
WO2005000307A1 (fr) 2003-06-26 2005-01-06 Santen Pharmaceutical Co., Ltd. Composition ophtalmique contenant des quinolones et procede d'utilisation
EP1648563B1 (fr) * 2003-07-30 2007-09-19 Otsuka Pharmaceutical Co., Ltd. Derives carbostyrile pour accelerer la salivation
AU2005249274B2 (en) * 2004-06-04 2011-02-24 Camurus Ab Liquid depot formulations
MX2007000748A (es) * 2004-07-22 2007-03-28 Genentech Inc Metodos para tratar el sindrome de sjogren.
BRPI0517451A (pt) * 2004-10-25 2008-10-07 Bausch & Lomb composição oftámilca, e, métodos de tratar conjutivite alérgica e doença de olho seco
US7247623B2 (en) * 2005-08-19 2007-07-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with non-drying antihistamines
EP2002841A4 (fr) * 2006-03-23 2009-04-15 Senju Pharma Co Composition ophtalmique comprenant de la gomme de xanthane et du glucose
US20080139531A1 (en) * 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
NZ578638A (en) * 2007-02-02 2010-12-24 Pfizer Prod Inc Tricyclic compounds and their use as glucocorticoid receptor modulators
US20090286718A1 (en) * 2008-01-04 2009-11-19 Sirion Therapeutics, Inc. Stable Aqueous Cyclosporin Compositions
WO2010047681A1 (fr) * 2008-10-24 2010-04-29 Bridge Pharma, Inc. Traitement de xérophthalmie à l'aide de norkétotifène
WO2010059894A1 (fr) 2008-11-21 2010-05-27 Bridge Pharma, Inc. Formations oculaires de norkétotifène

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207684B1 (en) * 1997-06-09 2001-03-27 Bridge Pharma, Inc. Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use
US20020037883A1 (en) * 2000-07-26 2002-03-28 Alcon Universal Ltd. Process for manufacturing compositions containinig ciprofloxacin and hydrocortisone

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066052A1 (fr) * 2015-10-15 2017-04-20 Bridge Pharma, Inc. Formulations et méthodes de traitement de pression intraoculaire élevée

Also Published As

Publication number Publication date
US20140303091A1 (en) 2014-10-09
US8969385B2 (en) 2015-03-03
US8765787B2 (en) 2014-07-01
US20100130550A1 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
US8969385B2 (en) Ocular formulations of norketotifen
US12070466B2 (en) D2O stabilized pharmaceutical formulations
JP7489965B2 (ja) マルチキナーゼ阻害剤のエマルジョン製剤
JP5836473B2 (ja) 眼科用組成物
AU2010333039B2 (en) Pharmaceutical composition for treatment of dry eye syndrome
US20230042785A1 (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
WO2020018498A1 (fr) Formulations de cyclodextrine
US9694003B2 (en) Formulations and methods for treating high intraocular pressure
EP2278953B1 (fr) Émulsions à auto-préservation
EA034839B1 (ru) Офтальмологический раствор
US20240139166A1 (en) Ophthalmic compositions for presbyopia
US20150352176A1 (en) Oil-free and fat-free aqueous suspensions of cyclosporin
KR102268002B1 (ko) 효과 지속성 점안제 조성물
JP6522592B2 (ja) １ｈ−インドール−１−カルボキサミド誘導体を含有する局所水性眼科用組成物および眼疾患の治療へのその使用
EP2827838B1 (fr) Composition pharmaceutique ophtalmique contenant un inhibiteur d'anhydrase carbonique et procédé pour sa préparation
US11850221B2 (en) Ophthalmic pharmaceutical compositions and uses thereof
US20240165147A1 (en) Methods for Treating Eyetear Film Deficiency
US20230338541A1 (en) Use of high molecular weight hyaluronic acid as ocular transporting vehicle
WO2024209038A1 (fr) Utilisation de pimecrolimus pour le traitement de la sécheresse oculaire chez des patients caractérisés par un score de coloration cornéenne de 4 ou 5 sur l'échelle de classification d'oxford
TW202342108A (zh) 多劑量眼用組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09828262

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09828262

Country of ref document: EP

Kind code of ref document: A1